Recombinant Zebrafish ACOT9.2

• Cat.No.: ACOT9.2-3524Z
• Product Overview: Recombinant Zebrafish ACOT9.2 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: acot9.2 acyl-CoA thioesterase 9, tandem duplicate 2 [ Danio rerio (zebrafish) ]
• Official Symbol: ACOT9.2
• Gene ID: 798008
• mRNA Refseq: NM_001037399
• Protein Refseq: NP_001032476
• UniProt ID: Q32PS1

Q&As

How is the expression of ACOT9.2 protein regulated in cells?

The exact regulation of ACOT9.2 protein expression is still being studied, but it is known to be regulated by various factors such as dietary fatty acids and hormones such as insulin. Additionally, genetic factors may also play a role in its expression.

Could ACOT9.2 be used as a biomarker for certain diseases or conditions?

There is currently no evidence to suggest that ACOT9.2 could be used as a biomarker for any specific disease or condition.

How could the inhibition or activation of ACOT9.2 be used in clinical applications?

Inhibition of ACOT9.2 could potentially be used as a therapeutic strategy to improve glucose homeostasis and insulin sensitivity in conditions such as type 2 diabetes. Conversely, activation of ACOT9.2 may be useful for the treatment of certain metabolic disorders or conditions characterized by high levels of circulating fatty acids.

How could the study of ACOT9.2 contribute to our understanding of metabolic disorders?

Studying the function and regulation of ACOT9.2 in the context of lipid metabolism and insulin sensitivity may provide insights into the pathogenesis and potential therapeutic targets for metabolic disorders such as type 2 diabetes and obesity.

Can ACOT9.2 protein be used in drug development?

ACOT9.2 protein has been shown to play a role in lipid metabolism and its inhibition has been linked to improved glucose homeostasis and insulin sensitivity in animal models. Therefore, small molecule inhibitors targeting ACOT9.2 protein may be developed for treating metabolic disorders such as obesity and diabetes.

Is ACOT9.2 protein being used in clinical trials?

To our knowledge, ACOT9.2 protein is not currently being used in clinical trials. However, preclinical studies have shown potential for its use in treating metabolic disorders, and further research may lead to its clinical applications.

Are there any known side effects associated with inhibiting ACOT9.2 protein?

To our knowledge, there have been no reported clinical studies investigating the effects of inhibiting ACOT9.2 protein in humans. However, preclinical studies have suggested that inhibition of ACOT9.2 can improve glucose homeostasis and insulin sensitivity without causing any adverse effects, suggesting it may be a safe target for therapeutic intervention.

How can ACOT9.2 protein be applied in biotechnology?

ACOT9.2 protein can potentially be used in biotechnology for the production of biofuels and other value-added chemicals. It has been shown to play a role in the hydrolysis of ester bonds in fatty acids, which is a key step in the production of fatty acid-derived biofuels and chemicals.

Can ACOT9.2 protein be used in personalized medicine?

Like ACOT9.1 protein, ACOT9.2 protein may hold potential for use in personalized medicine. Its expression and activity can be influenced by various factors such as diet and genetic factors, suggesting that personalized treatments targeting ACOT9.2 may be beneficial for certain individuals.

Has the role of ACOT9.2 been studied in relation to cancer?

There is currently limited research investigating the role of ACOT9.2 in cancer. However, some studies have suggested that members of the ACOT family, including ACOT9.2, may play a role in lipid metabolism and signaling pathways that are dysregulated in certain types of cancer.

What are the challenges in developing therapies targeting ACOT9.2 protein?

Developing therapies targeting ACOT9.2 protein may face similar challenges to those targeting ACOT9.1, such as specificity of targeting and potential off-target effects. Additionally, further studies are needed to elucidate the full extent of ACOT9.2's role in lipid metabolism and its potential use in human diseases.

Are there any drugs or compounds currently being developed to target ACOT9.2?

To our knowledge, there are no drugs or compounds currently being developed specifically to target ACOT9.2. However, there are several compounds that target other members of the ACOT family, which may have similar effects on lipid metabolism and insulin sensitivity.